Skip to content

Author

Mehmet Kanbay

We have 6 of 86 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Pleiotropic Endocrine Functions of Bone in Chronic Kidney Disease

The principal organs involved in the control of mineral homeostasis are the kidneys, parathyroid glands, intestine and bone, which interact in a finely coordinated manner to maintain calcium and phosphorus levels. Mineral balance is disrupted in the context of chronic kidney disease (CKD), triggering compensatory mec...

Juan Miguel Diaz-Tocados, Juan Diego Domínguez-Coral, M. D. de Borst et al. · 0 citations
Review Oct 2026

Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies.

Aldosterone, the terminal effector of the renin-angiotensin-aldosterone system, regulates sodium retention, potassium excretion, and blood pressure. Beyond these classical effects, aldosterone-associated and mineralocorticoid receptor (MR)-mediated signaling is implicated in inflammation, oxidative stress, fibrosis, al...

Mehmet Kanbay, Rama Al-Shiab, Ermeena Shah et al. · 0 citations
Review Open access Sep 2026

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis.

BACKGROUND AND AIMS Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and kidney outcomes, but their effects on circulating inflammatory biomarkers remain uncertain. We systematically reviewed randomized evidence on the effects of SGLT2is on peripheral-blood inflammatory biomarkers. METHODS P...

Mehmet Kanbay, Ermeena Shah, Rama Al-Shiab et al. · 0 citations
Review Sep 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes

Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...

Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al. · 1 citation
Review Open access Aug 2026

Integrating kidney imaging for risk prediction, therapeutic monitoring, and prognostication across the kidney disease spectrum: a review of emerging evidence

Kidney imaging advances are transforming the field of nephrology by allowing non-invasive examination of renal structure, function, and pathology, and imaging biomarkers show significant predictive value for progression to kidney failure in CKD, including diabetic kidney disease, independent of traditional measurements...

Mustafa Guldan, Ibrahim Gulmaliyev, Rama Al-Shiab et al. · 0 citations
Review Open access Sep 2026

Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis

ABSTRACT Chronic kidney disease (CKD)-associated osteoporosis is present in approximately 25% of all patients with CKD. The occurrence increases as kidney function declines, with prevalences up to 75% in elderly dialysis patients. It is often undiagnosed due to the perception that limited treatment options are availabl...

Ditte Hansen, Hanne Skou-Jørgensen, Mehmet Kanbay et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.